ArticleDermatology and therapy2025
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
Who cites it
3 citing papers in PubMed.
- Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies-A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Deucravacitinib in dermatology: current indication and existing off-label data.Drugs in context · 2026Review
- Biologics and small molecules for psoriasis: current and future progress.Drugs in context · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFor patients with psoriasis, psoriatic arthritis can be a painful comorbid condition that is often undiagnosed. It is therefore essential that more research is done to understand which treatments for psoriasis relieve both dermatologic and joint symptoms. This analysis aimed to compare the effects of deucravacitinib vs. placebo or apremilast on joint pain and the impact of musculoskeletal symptoms at weeks 16 and 24 in patients from the POETYK psoriasis (PSO-1; NCT03624127) and POETYK PSO second (PSO-2; NCT03611751) trials who self-reported joint symptoms.
methodsDuring screening in each trial, patients with psoriasis who reported musculoskeletal complaints completed the self-administered Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire. Scores of ≥ 47 constituted positive screens (PASE positive). Joint pain and the impact of musculoskeletal symptoms were measured using a visual analog scale (VAS), with higher scores denoting worse disease burden.
resultsThis pooled analysis included 185 patients who screened as PASE-positive in the combined POETYK PSO-1 and PSO-2 trials. Improvement from baseline was greater in patients treated with deucravacitinib vs. placebo at week 16 for joint pain VAS (- 15.2 vs. - 3.2) and joint disease VAS (- 17.4 vs. - 3.8). Improvements from baseline were also greater for patients treated with deucravacitinib vs. apremilast for joint pain VAS (- 22.8 vs. - 8.6) and joint disease VAS (- 19.6 vs. - 8.8) scores at week 24. Greater proportions of deucravacitinib-treated patients also achieved 30%, 50%, and 70% improvements in joint pain and musculoskeletal symptoms and impact VAS scores at weeks 16 and 24 than those who received placebo or apremilast.
conclusionFindings from this pooled analysis suggest that deucravacitinib may be used in patients with psoriasis to effectively treat both dermatologic and joint symptoms. Graphical abstract available for this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.